Latest News

Lytix Biopharma strengthens patent protection of lead candidate LTX-315 in the US

Lytix Biopharma second quarter and first half of 2021 results: Fueled to target the US cancer market

Lytix Biopharma presents first half and second quarter 2021 results, Friday 27 August

Lytix Biopharma initiates the Phase II combination study in the US with LTX-315 and Pembrolizumab in patients with solid tumors